Differential role of circulating endothelial progenitor cells in cirrhotic patients with or without hepatocellular carcinoma

Digestive and Liver Disease

Volumn 41, Issue 12, 2009, Pages 902-906

  Sieghart, W ^a   Fellner, S ^a   Reiberger, T ^a   Ulbrich, G ^a   Ferlitsch, A ^a   Wacheck, V ^a   Peck Radosavljevic, M ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Cirrhosis; Endothelial progenitor cells; Hepatocellular carcinoma; Portal hypertension

Indexed keywords

CD133 ANTIGEN; CD34 ANTIGEN; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ADULT; AGED; ARTICLE; BLOOD CELL; CONTROLLED STUDY; CORRELATION ANALYSIS; DATA ANALYSIS; ENDOTHELIAL PROGENITOR CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER VEIN; MAJOR CLINICAL STUDY; MALE; PORTAL HYPERTENSION; PRESSURE GRADIENT; PRIORITY JOURNAL; PROGNOSIS; STAINING; STEM CELL;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; CARCINOMA, HEPATOCELLULAR; ENDOTHELIAL CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMANS; HYPERTENSION, PORTAL; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; STATISTICS, NONPARAMETRIC; STEM CELLS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VENOUS PRESSURE;

EID: 70350573516     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dld.2009.04.013     Document Type: Article

References (32)

1. Coultas L., Chawengsaksophak K., and Rossant J. Endothelial cells and VEGF in vascular development. Nature 438 (2005) 937-945
2. Peichev M., Naiyer A.J., Pereira D., et al. Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors. Blood 95 (2000) 952-958
3. Werner N., Kosiol S., Schiegl T., et al. Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med 353 (2005) 2613-2616
4. Grisar J., Aletaha D., Steiner C.W., et al. Depletion of endothelial progenitor cells in the peripheral blood of patients with rheumatoid arthritis. Circulation 111 (2005) 204-211
5. Urbich C., and Dimmeler S. Endothelial progenitor cells: characterization and role in vascular biology. Circ Res 95 (2004) 343-353
6. Vasa M., Fichtlscherer S., Adler K., et al. Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease. Circulation 103 (2001) 2885-2890
7. Zhang H., Vakil V., Braunstein M., et al. Circulating endothelial progenitor cells in multiple myeloma: implications and significance. Blood 105 (2005) 3286-3294
8. Ho J.W., Pang R.W., Lau C., et al. Significance of circulating endothelial progenitor cells in hepatocellular carcinoma. Hepatology 44 (2006) 836-843
9. Bogos K., Renyi-Vamos F., Dobos J., et al. Identification and clinical significance of circulating endothelial progenitor cells in human non-small cell lung cancer. Cancer Res 66 (2006) 7341-7347
10. Vasa M., Fichtlscherer S., Aicher A., et al. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res 89 (2001) e1-e7
11. Bruix J., Boix L., Sala M., and Llovet J.M. Focus on hepatocellular carcinoma. Cancer Cell 5 (2004) 215-219
12. Poon R.T., Ng I.O., Lau C., et al. Serum vascular endothelial growth factor predicts venous invasion in hepatocellular carcinoma: a prospective study. Ann Surg 233 (2001) 227-235
13. Poon R.T., Ho J.W., Tong C.S., Lau C., Ng I.O., and Fan S.T. Prognostic significance of serum vascular endothelial growth factor and endostatin in patients with hepatocellular carcinoma. Br J Surg 91 (2004) 1354-1360
14. Semela D., and Dufour J.F. Angiogenesis and hepatocellular carcinoma. J Hepatol 41 (2004) 864-880
15. Yu D., Sun X., Qiu Y., et al. Identification and clinical significance of mobilized endothelial progenitor cells in tumor vasculogenesis of hepatocellular carcinoma. Clin Cancer Res 13 (2007) 3814-3824
16. Angermayr B., Fernandez M., Mejias M., Gracia-Sancho J., Garcia-Pagan J.C., and Bosch J. NAD(P)H oxidase modulates angiogenesis and the development of portosystemic collaterals and splanchnic hyperaemia in portal hypertensive rats. Gut 56 (2007) 560-564
17. Fernandez M., Vizzutti F., Garcia-Pagan J.C., Rodes J., and Bosch J. Anti-VEGF receptor-2 monoclonal antibody prevents portal-systemic collateral vessel formation in portal hypertensive mice. Gastroenterology 126 (2004) 886-894
18. Fernandez M., Mejias M., Angermayr B., Garcia-Pagan J.C., Rodés J., and Bosch J. Inhibition of VEGF receptor-2 decreases the development of hyperdynamic splanchnic circulation and portal-systemic collateral vessels in portal hypertensive rats. J Hepatol 43 (2005) 98-103
19. Fernandez M., Mejias M., Garcia-Pras E., Mendez R., Garcia-Pagan J.C., and Bosch J. Reversal of portal hypertension and hyperdynamic splanchnic circulation by combined vascular endothelial growth factor and platelet-derived growth factor blockade in rats. Hepatology 46 (2007) 1208-1217
20. Ward N.L., Haninec A.L., Van Slyke P., et al. Angiopoietin-1 causes reversible degradation of the portal microcirculation in mice: implications for treatment of liver disease. Am J Pathol 165 (2004) 889-899
21. Angermayr B., Mejias M., Gracia-Sancho J., Garcia-Pagan J.C., Bosch J., and Fernandez M. Heme oxygenase attenuates oxidative stress and inflammation, and increases VEGF expression in portal hypertensive rats. J Hepatol 44 (2006) 1033-1039
22. Tugues S., Fernandez-Varo G., Munoz-Luque J., et al. Antiangiogenic treatment with sunitinib ameliorates inflammatory infiltrate, fibrosis, and portal pressure in cirrhotic rats. Hepatology 46 (2007) 1919-1926
23. Taniguchi E., Kin M., Torimura T., et al. Endothelial progenitor cell transplantation improves the survival following liver injury in mice. Gastroenterology 130 (2006) 521-531
24. Nakamura T., Torimura T., Sakamoto M., et al. Significance and therapeutic potential of endothelial progenitor cell transplantation in a cirrhotic liver rat model. Gastroenterology 133 (2007) 91-107
25. Bosch J., Garcia-Pagan J.C., Berzigotti A., and Abraldes J.G. Measurement of portal pressure and its role in the management of chronic liver disease. Semin Liver Dis 26 (2006) 348-362
26. Poon R.T., Lau C., Pang R., Ng K.K., Yuen J., and Fan S.T. High serum vascular endothelial growth factor levels predict poor prognosis after radiofrequency ablation of hepatocellular carcinoma: importance of tumor biomarker in ablative therapies. Ann Surg Oncol 14 (2007) 1835-1845
27. Hill J.M., Zalos G., Halcox J.P.J., et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 348 (2003) 593-600
28. Umemura T., Soga J., Hidaka T., et al. Aging and hypertension are independent risk factors for reduced number of circulating endothelial progenitor cells. Am J Hypertens 21 (2008) 1203-1209
29. Dittmar T., Heyder C., Gloria-Maercker E., Hatzmann W., and Zanker K.S. Adhesion molecules and chemokines: the navigation system for circulating tumor (stem) cells to metastasize in an organ-specific manner. Clin Exp Metastasis 25 (2008) 11-32
30. Willett C.G., Boucher Y., di Tomaso E., et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 10 (2004) 145-147
31. Siegel A.B., Cohen E.I., Ocean A., et al. Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol 26 (2008) 2992-2998
32. Martins A., Cortez-Pinto H., Marques-Vidal P., et al. Treatment and prognostic factors in patients with hepatocellular carcinoma. Liver Int 26 (2006) 680-687